Summary.-One hundred and thirty-nine untreated patients with acute myelogenous leukaemia (AML) were admitted between August 1970 and December 1973 and allocated into two remission treatment regimens: one to receive chemotherapy alone and the other chemotherapy with immunotherapy. Of the patients who attained remission, 22 were in the chemotherapy group and in September 1975 2 remained alive, the median survival time being 270 days and after relapse 75 days. Twenty-eight patients received immunotherapy during remission, and 5 remained alive; the median survival time of the group being 510 days and after relapse 165 days. Ongoing actuarial analysis precisely predicted early in the study the median survival of the two groups, but it took a 2-year follow-up after entry of the last patient before it became clear that there were very few long-term survivors. The increase in survival time produced by the immunotherapy is apparently made up of two components: prolongation of the first remission and length of survival after the first relapse. It must be noted that the chemotherapy for this study was devised 6 years ago and the results of the control arm (chemotherapy alone) may be poorer than those obtained in contemporary studies.
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IN AUGUST 1970 a study was initiated to determine if BCG and leukaemia cells could be used for the treatment of patients with acute myelogenous leukaemia (AML) during the remission phase of their disease. The first analysis of the results of this trial was published in 1973 (Powles et al., 1973a) shortly before the last patient had been admitted to the study. It was found that the patients who had received immunotherapy plus intermittent chemotherapy during remission lived significantly longer than those who had received the same chemotherapy alone. Moreover, at that time, life table analysis indicated that immunotherapy produced a survival curve that had a tail indicating that some of these patients might have a very prolonged survival. The data available in 1973 also showed that the median length of the first remission for patients receiving immunotherapy was prolonged by 66%, but because of the variation in the remission length within the two groups, the overall difference was not statistically significant at the 5 % level. In this paper we report the outcome of the follow-up of this trial for a further period of 21 years. As the trial was closed towards the end of 1973, this means that all the patients have been followed for at least 2 years. The historical background and scientific basis for this study has already been described (Powles et at., 1973a) . Powles et al., 1973a) consists of daunorubicin and cytosine arabinoside given in slightly modified ways (Studies 2, 3, 4A and 4B-Crowther et at., 1970, 1973) . Fifty-three patients passed into full remission, so that the overall remission rate during the trial period now stands at 38%. All patients in remission in Studies 2, 3 and 4A received the identical maintenance chemotherapy described by Powles et al. (1973a) , which consisted of 5-day courses of cytosine arabinoside and daunorubicin alternating with 5 days of cytosine arabinoside and 6-thioguanine. Between every 5 days of treatment there was a 23-day gap, and it was during this period that patients received immunotherapy. The patients in Study 4B were all aged over 60 years, and their maintenance chemotherapy consisted of 3-day courses every 2 weeks. All patients stopped maintenance chemotherapy after one year (12 courses), and thereafter the chemo-immunotherapy patients received only immunotherapy and the chemotherapy patients received no further treatment.
Immunotherapy.-Immunotherapy was started whenever possible just before complete remission, at a time when the marrow was hypoplastic. In all instances, subsequent marrow biopsies confirmed that these patients had achieved a full remission. The immunotherapy, described in detail previously (Powles et al., 1973a) , consisted of weekly BCG (Glaxo) and 109 irradiated allogeneic myeloblastic leukaemia cells given i.d. and s.c., and timed to avoid the 5-day courses of chemotherapy. All 4 limbs received the BCG in turn, one weekly, and the cells were injected into the other 3 limbs. The cells were collected in a manner described previously (Powles et al., 1974) using an NCI/IBM Blood Cell Separator and preserved in a viable state at -179°C in the presence of DMSO (Powles et al., 1973b) . Individual patients received cells from the same donor for as long as possible.
Treatment after relapse.-When patients relapsed, the initial induction treatment with daunorubicin and cytosine arabinoside was repeated whenever possible. If no regression of leukaemia was seen, the treatment was usually changed to a combination of cyclophosphamide and 6-thioguanine. If remission occurred, the maintenance treatment was modified to a single injection of daunorubicin and 3 days of cytosine arabinoside followed 11 days later by 3 days of oral cyclophosphamide and 6-thioguanine. After another 11-day gap the whole cycle was repeated, with maintenance chemotherapy for 3 days every fortnight. Those patients who previously received immunotherapy were given further treatment with BCG and a different population of irradiated AML cells. Tables I and II give the clinical details at presentation, remission lengths and survival time for each of the patients in the two arms of the trial. At this time, August 1975, 5/28 patients in the chemoimmunotherapy arm remained alive, although 4 of these had relapsed; 2/22 patients on chemotherapy were alive, both still in their first remission. The actuarial analysis of the duration of survival of these patients after attaining remission is given in Fig. 1 . The median duration of survival of the chemotherapy group is 270 days, and that for the chemo-immunotherapy group 510 days. Statistical analysis of survival data calculated by the " logrank " non-parametric method (Peto and Pike, 1973) gives an overall chisquared for the differences between these two groups of 4-48; P 0 0-03. One of the 3 immunotherapy patients excluded from the analysis died in remission at Day 0, prior to immunotherapy, and the other 2 patients remained alive at the time of analysis at 465 and 655 days. Their exclusion therefore does not materially affect the analysis. Fig. 2 shows the actuarial analysis for the length of first remission; the median durations being 305 days for the chemoimmunotherapy group and 191 days for the chemotherapy group. However, the overall difference between the two groups was not statistically significant at the 5% level.
RESULTS
The actuarial analysis of the length of survival after relapse for the two groups of patients is shown in Fig. 3 
Mechani8ms of prolongation of life by immunotherapy
There is a high probability that adding immunotherapy to the intermittent chemotherapy given as a maintenance treatment during remission extended the length of survival of patients in our study. Two distinct components can contribute to this effect: (1) prolongation of the length of the first remission, and (2) extension of the length of survival after relapse. The present study did not allow us to decide whether the length of the first remission was extended by the immunotherapy, because the 60% difference in the median was not statistically secure. The inability Fig. 4 , except that the standard actuarial method of analysis has been used. Each time a patient dies the curve drops by an amount proportional to the number of patients who have reached and had the chance to die at that moment in time.
to resolve this aspect in this trial was due to the wide variation in remission lengths within each group, and this makes it possible that the observed difference may have arisen by chance, in view of the small number of patients in each group. It is therefore fruitless to speculate whether the administration of BCG and leukaemic cells during remission has produced in patients with AML an effect like that seen in experimental animals, where similar therapies heightened the capacity of the host to contain residual malignant cells (Alexander and Hall, 1970) . It is unlikely that prolongation of survival after relapse was due to the immunotherapy increasing the immune reaction of the host against leukaemiaspecific antigens, and it seems more probable that this effect was produced by stimulation of the bone-marrow, which permitted patients who had received immunotherapy and who had then relapsed, to tolerate the high doses of cytotoxic chemotherapy necessary to constrain the disease. Such an effect has been seen in animal systems (Wolmark, Levine and Fisher, 1974; Dimitrov et al., 1975) and cotuld be important, because patients who relapse usually die from bone marrow failure. The outcome of our study was therefore disappointing, since we cannot tell if we achieved an effect of specific active immunotherapy. Furthermore, the chemotherapy regime used for this study was devised 6 years ago, and it is possible that current studies using chemotherapy alone may produce better survival results than our control arm and not differ significantly from our chemo-immunotherapy results.
A group in Manchester (Freeman et al., 1973) followed the same immunotherapy protocol as used here, and, whilst they did not carry controls in their clinical trial, they commented on the ease with which patients who had received immunotherapy without maintenance chemotherapy achieved a second remission, and also noted the long period of survival after relapse in this group.
Relative contribution of leukaemia cells and of BCG in extending life after relapse In many animal systems, the immunotherapeutic effect achieved by systemic administration of BCG is much inferior to that produced by inoculation of killed tumour cells at multiple sites (Haddow and Alexander, 1964; Parr, 1972 (Gutterman et al., 1974) . While they claim a distinct benefit from the use of BCG in maintaining AML patients in remission, criticism of the statistical analysis and data in this study (Peto and G-alton, 1975 ) must lead to reservations concerning the significance of these conclusions. More recently, a controlled study by Leukaemia Group B in the U.S.A. (Bekesi, Roboz and Holland, 1977) has claimed that neuraminidase-treated AML cells (with or without an extract of tubercle bacillus MER) given to patients receiving chemotherapy, has produced a highly significant prolongation of remis-sion, when compared with patients with chemotherapy alone. Time must elapse before the significance of these three studies can be fully appreciated, particularly concerning the possibility of a group of patients becoming long-term survivors.
CONCLUSION
It is obvious that this trial has raised more questions than it has answered. From a clinical point of view it is useful, in that it has shown that a relatively atraumatic type of maintenance treatment (i.e., BCG plus irradiated leukaemia cells) extends the life of patients with AML, though without curing a significant number of them. Further progress in the treatment of AML, by methods other than the use of cytotoxic chemotherapeutic agents, requires the measurement of the reaction (if any) of the host against his tumour, so that it can be determined whether " immunotherapy " has a place in the treatment of this disease. The first requirement for such studies is to establish whether patients with AML are capable of reacting to a macromolecule in the membrane of their leukaemia cells, and the subsequent paper constitutes our approach to this problem.
